BIO
Bio-Rad Navigates Uncertain Waters with Resilient Q1 Performance
Despite the ongoing conflict in the Middle East, Bio-Rad's first quarter 2026 results showed resilience, with the company reporting revenue within its guidance. The region has been one of Bio-Rad's fastest-growing markets for several years, representing over 9% of their diagnostic segment primarily driven by their